At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 209 enrolled
Drug / intervention
Maravirocdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Open Label, Non-Comparative Safety Study Of Maraviroc
In Brief
A Phase 3 clinical trial evaluating Maraviroc for Acquired Immunodeficiency Syndrome and HIV Infection. Completed, enrolled 209 participants across 16 sites.
Detailed Summary
To collect safety and tolerability data in a more diverse patient population of patients with HIV/Aids, who have limited therapeutic options.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcquired Immunodeficiency Syndrome, HIV Infection
CountriesBrazil
CollaboratorsPfizer
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 2007
Enrollment StartJul 2007
Primary CompletionAug 2010
Study CompletionSep 2010
TodayJul 2026
First PostedMay 24, 2007
Enrollment StartJul 1, 2007
Primary CompletionAug 1, 2010
Study CompletionSep 1, 2010
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 19.1 years ago
Interventions
Maravirocdrug
Maraviroc should be dosed BID with total dose adjusted according to the other drugs the patient is taking. Maraviroc may be taken with or without food. The subject should only take missed doses if it is not within 6 hours prior to the planned next dose. No dose adjustment of OBT is required due to the presence of maraviroc.